Molbio Diagnostics Eyes ₹940 Crore Through IPO for Expansion

Molbio Diagnostics, a leading name in molecular diagnostics, is preparing to raise ₹940 crore through an initial public offering (IPO) aimed at funding capital expenditures and reducing promoter stake. The company intends to generate ₹200 crore via a fresh issue of shares, while an additional ₹740 crore will be garnered through an offer for sale. Post-IPO, the promoter group's stake is expected to decrease from 46.6% to 43%.

Global Presence and Revenue Drivers

Operating six manufacturing facilities across India, Molbio Diagnostics serves clients in over 90 countries. The company's clientele includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A significant portion of its revenue, over 50%, is attributed to its top clients, highlighting a concentration risk for investors.

Founded in 2000, Molbio Diagnostics has made a mark with its 'Truenat' platform, a portable diagnostic system that delivers accurate results within an hour, particularly suited for resource-limited settings. The company offers over 30 disease testing solutions through 43 diagnostic assays. A substantial 74% of its revenue stems from the sale of test kits, with tuberculosis diagnostic kits accounting for 70% of this figure.

Financial Performance and Market Position

Between fiscal years 2024 and 2026, Molbio's revenue from operations increased by 31.5% annually to ₹1,445.7 crore, while net profit grew by 40.2% annually to ₹164.1 crore. The company also reported a 33.2% increase in operating profit before interest, tax, depreciation, and amortization (EBITDA) to ₹328.2 crore, with EBITDA margins improving to 22.6% in FY26 from 22% in FY24.

In FY26, year-on-year revenue saw a 41.7% jump, alongside a 27.9% rise in EBITDA and an 18.4% increase in net profit. The company's valuation post-IPO demands a price-earnings (P/E) multiple of up to 57, which is competitive when compared to other healthcare diagnostics and medical device firms like Poly Medicure and Dr. Lal PathLabs, whose P/E multiples range between 54 and 81.

Investor Considerations

Molbio Diagnostics' IPO presents an opportunity for high-risk investors seeking long-term growth potential. The company's strategic focus on expanding its product offerings and enhancing its manufacturing capabilities positions it well for future growth. However, the concentration of revenue from a few key clients and reliance on tuberculosis test kits are factors that investors should consider carefully.

As Molbio Diagnostics embarks on this significant financial endeavor, it aims to solidify its position in the global diagnostics market, leveraging its innovative solutions and strong presence in international healthcare sectors.